LIST OF DRUG CANDIDATES TARGETING NASH
(updated weekly)

Click on the name of drug to access data sheet 


OCALIVA (OCA), Laboratory : INTERCEPT

Type of drug : FXR Agonist

Clinical trials advancement : Ongoing Phase 3

The drug got the Breakthrough Therapy Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 30


ELAFIBRANOR (GFT505), Laboratory : GENFIT

Type of drug : dual PPAR alpha delta agonist

Clinical trials advancement : Recruiting Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 36


CENICRIVIROC, Laboratory : ALLERGAN

Type of drug : CCR2CCR5 Antagonist

Clinical trials advancement : Initiating Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 43


SELONSERTIB (GS-4997), Laboratory : GILEAD

Type of drug : (ASK1) inhibitor

Clinical trials advancement : Initiating Phase 3

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 47


GR_MD_02, Laboratory : GALECTIN

Type of drug : Galectin Inhibitor

Clinical trials advancement : Ongoing Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 58


BMS986036, Laboratory : Bristol-MyersSquibb

Type of drug : PEG-FGF21

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 76


ARAMCHOL, Laboratory : GALMED

Type of drug : FABACs

Clinical trials advancement : Ongoing Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 68


LJN452, Laboratory : NOVARTIS

Type of drug : non-BA FXR agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 87


MGL_3196, Laboratory : MADRIGAL

Type of drug : THR-β Agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 88


MSDC_0602, Laboratory : OCTETA

Type of drug : mTOT modulating insulin sensitizer

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 88


EMRICASAN (IDN-6556, PF-03491390), Laboratory : CONATUS

Type of drug : potent inhibitor of caspase-mediated pro-inflammatory cytokines

Clinical trials advancement : Recruiting Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 71


GS9674, Laboratory : GILEAD

Type of drug : FXR agonist

Clinical trials advancement : Recruiting Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 72


VOLIXIBAT (SHP626), Laboratory : SHIRE

Type of drug : (ASBT) inhibitor

Clinical trials advancement : Recruiting Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 72


IMM124E, Laboratory : IMMURON

Type of drug : anti-LPS antibodies and adjuvants

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 91


LMB763, Laboratory : NOVARTIS

Type of drug : ?

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 91


SEMAGLUTIDE, Laboratory : NOVONORDISK

Type of drug : GLP_1analog

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 93


SAROGLITAZAR, Laboratory : ZYDUS

Type of drug : dual PPAR-α γ agonist

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 99


IVA337, Laboratory : INVENTIVA

Type of drug : tri PPAR α δ γ

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 100


NGM282, Laboratory : NGMBioPHARM

Type of drug : FGF19 hormon

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 100


GRI_0621, Laboratory : GRIPharma

Type of drug : NKT I Inhibitor

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 100


GS0976, Laboratory : GILEAD

Type of drug : ACC inhibitor

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 104


VK2809, Laboratory : VIKING

Type of drug : ?

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 106


MN_001, Laboratory : MEDICINOVA

Type of drug : (5-LOLT) inibitor

Clinical trials advancement : Recruiting Phase 2a

Estimated Time to market in months : 109


PXS_4728A, Laboratory : PHARMAXIS

Type of drug : SSAO inhibitor

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 111


NAMODENOSON, Laboratory : CANFITE

Type of drug : A3AR activation

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 111


GEMCABENE, Laboratory : GEMPHIRE

Type of drug : enhance the clearance of VLDLs and may also inhibit ACC

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 111


KBP_042, Laboratory : NORDICBIOSCIENCE

Type of drug : (DACRA)

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 111


NGM313, Laboratory : NGMBio

Type of drug : KLB-FGFR1c

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 113


CER_209 (CER_209), Laboratory : CERENIS

Type of drug : P2Y13 receptor agonist

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 115


BMS_986171, Laboratory : Bristol-MyersSquibb

Type of drug : ?

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 115


RTU_1096, Laboratory : SUCAMPO

Type of drug : Vap-1 inhibitor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 116


AZD4076, Laboratory : ASTRAZENECA

Type of drug : miR-103107 inhibitor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 116


ND_L02_s0201, Laboratory : NITTODENKO

Type of drug : (SERPINH1) (Hsp47)

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 116


IONIS_DGAT2Rx, Laboratory : IONISPHARMA

Type of drug : DGAT2Rx

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 117


DRX_065, Laboratory : DeuteRx

Type of drug : stabilized, preferred enantiomer of pioglitazone

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 117


INT_767, Laboratory : INTERCEPT

Type of drug : farnesoid X receptor (FXR) and TGR5, a G-protein coupled bile acid receptor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 119


EDP_305, Laboratory : ENANTA

Type of drug : FXR agonist

Clinical trials advancement : Ongoing Phase 1

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 101


NC_001, Laboratory : NAIAPHARMA

Type of drug : act on insulin resistance

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 122


VK0214, Laboratory : VIKING

Type of drug : TRβ agonist

Clinical trials advancement : Preclinic

Estimated Time to market in months : 123


TGFTX4, Laboratory : GENFIT

Type of drug : ?

Clinical trials advancement : Preclinic

Estimated Time to market in months : 124


JH_0920 (JH_0920), Laboratory : JOYCEBiotech

Type of drug : inhibit anaerobic metabolism in eukaryotic

Clinical trials advancement : Preclinic

Estimated Time to market in months : 124


VPR_423 (VPR_423), Laboratory : VisionaryPharmaceuticals

Type of drug : RORgammaT

Clinical trials advancement : Preclinic

Estimated Time to market in months : 124


RYI_018, Laboratory : CREATIVEBIOLAB

Type of drug : (CB-1)

Clinical trials advancement : Preclinic

Estimated Time to market in months : 124


GKT_137831, Laboratory : GENKYOTEC

Type of drug : NOX1&4 inhibitor

Clinical trials advancement : Preclinic

Estimated Time to market in months : 124


CB4209-CB4211 (CB4209-CB4211), Laboratory : CohBar

Type of drug : MOTS-c peptide analog

Clinical trials advancement : Preclinic

Estimated Time to market in months : 124


The dynamic list is here 



Share on StockTwits
FR-flag

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016